trending Market Intelligence /marketintelligence/en/news-insights/trending/aWho-4lyBkEyTKAXvqqpcw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Allergan reports results from trial of Botox in major depressive disorder

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Allergan reports results from trial of Botox in major depressive disorder

Allergan PLC reported topline data from a phase 2 study evaluating two different doses of Botox relative to placebo in adult females with major depressive disorder.

Primary endpoint for the study was change from baseline to week six in Montgomery-Asberg depression rating scale total score for the doses versus placebo, and a combination of the two doses compared with combined placebo groups.

The 30 units dose of the drug demonstrated numerically superior efficacy in total score on the Montgomery-Asberg depression rating scale compared to placebo, while the 50 units dose did not demonstrate superior efficacy over placebo.

Both secondary efficacy variables showed numerically superior efficacy over placebo and trended in the same direction as the primary efficacy variable for the 30 units dose, but not for 50 units dose.

Allergan chief research and development officer David Nicholson said in a statement that the company plans to move forward and develop a phase 3 program for a potential new treatment option for patients.